<DOC>
	<DOCNO>NCT03032588</DOCNO>
	<brief_summary>The main purpose study assess safety tolerability single dose JNJ-64152348 , inactivate poliovirus vaccine produce Sabin poliovirus strain PER.C6 cell ( sIPV ) healthy adult , use conventional inactivated poliovirus vaccine produce Salk poliovirus strain ( cIPV ) reference .</brief_summary>
	<brief_title>A First Human Study Assess Safety , Tolerability Immunogenicity Single Dose Trivalent Inactivated Poliovirus Vaccine Based Sabin Strains ( sIPV ) Given Intramuscularly Healthy Adults</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>Declared healthy investigator basis physical examination , medical history , vital sign clinical laboratory test perform screen . If result serum chemistry panel hematology outside normal reference range , participant may include investigator judge abnormalities deviation normal clinically significant . This determination must record participant 's source document initial investigator Heterosexual male participant must engage intercourse female partner childbearing potential use highly effective contraceptive method All female participant childbearing potential must negative urine betahuman chorionic gonadotropin ( betahCG ) pregnancy test screen immediately prior study vaccine administration Willing able adhere prohibition restriction specify protocol Agrees donate blood Week 4 visit Clinically significant neuropsychiatric , cardiovascular , pulmonary , liver renal insufficiency ( estimate creatinine clearance 60 milliliter per minute ( mL/min ) use CockcroftGault Equation ) ; metabolic , gastrointestinal , urologic , endocrine disease opinion investigator uncontrolled Any history malignancy ( exception squamous basal cell carcinoma skin carcinoma situ cervix , malignancy , consider cure minimal risk recurrence ) Previous severe allergic reaction vaccination polio vaccine Known allergy , hypersensitivity , intolerance one excipients JNJ64152348 , inactivate poliovirus vaccine produce Sabin poliovirus strain PER.C6 cell ( sIPV ) conventional inactivated poliovirus vaccine produce Salk poliovirus strain ( cIPV ) Received polio vaccine within 6 month study inclusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>